GlobeNewswire
-
Arch Biopartners Arranges Non-Brokered Private Placement
06/11/2026 -
Treace Medical Concepts Reports Third Quarter 2026 Financial Results
06/11/2026 -
Anika Reports Third Quarter 2026 Financial Results
06/11/2026 -
Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction System
06/11/2026 -
What Do Healthcare Sharing Programs Actually Cover, and What They Don’t
06/11/2026 -
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
06/11/2026 -
Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
06/11/2026 -
Korro to Present at the 2026 Jefferies Global Healthcare Conference in London
06/11/2026 -
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026 -
Spectral Medical Announces Third Quarter 2026 Financial Results and Provides Corporate Update
06/11/2026 -
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
06/11/2026 -
Eccogene to Present Preclinical Data of Small Molecule Amylin and Calcitonin Receptor Agonist ECC1542 at ObesityWeek® 2026
06/11/2026 -
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
06/11/2026 -
Groundbreaking therapy for advanced heart failure: Repairon’s Scientific Co-Founder, Prof. Wolfram-Hubertus Zimmermann, Receives the 2026 “Galenus-von-Pergamon” Award for Outstanding Basic Pharmacological Research
06/11/2026 -
Major shareholder announcement - BlackRock, Inc.
06/11/2026 -
Nature Medicine Publication Reveals How Human Movement Predicts Hidden Biosignals Spanning 18 Body Systems, from Heart and Liver Function to Metabolic and Mental Health
06/11/2026 -
Nxera Pharma Announces Vamorolone Selected for South Korea’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments
06/11/2026 -
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
06/11/2026 -
Le KFSH de Riyad figure parmi les 5 % des meilleurs établissements de santé au monde pour le tourisme médical selon le classement 2027 de Newsweek
06/11/2026
Pages